Pays: Canada
Langue: anglais
Source: Health Canada
LISINOPRIL
RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED
C09AA03
LISINOPRIL
5MG
TABLET
LISINOPRIL 5MG
ORAL
100/500
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0121550003; AHFS:
CANCELLED POST MARKET
2014-09-19
_ _ _ratio-LISINOPRIL P 5 mg, 10 mg and 20 mg Tablets _ _Page 1 of 37_ PRODUCT MONOGRAPH RATIO-LISINOPRIL P Lisinopril Tablets 5 mg, 10 mg and 20 mg USP Angiotensin Converting Enzyme Inhibitor ratiopharm inc. Canada J7J 1P3 Date of Preparation: August 31, 2007 Control Number: 081736, 109658 _ _ _ratio-LISINOPRIL P 5 mg, 10 mg and 20 mg Tablets _ _Page 2 of 37_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS................................................................................. 4 ADVERSE REACTIONS................................................................................................... 9 DRUG INTERACTIONS ................................................................................................. 14 DRUG INTERACTIONS ................................................................................................. 15 DOSAGE AND ADMINISTRATION............................................................................. 15 OVERDOSAGE ............................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 18 STORAGE AND STABILITY......................................................................................... 20 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 20 PART II: SCIENTIFIC INFORMATION .............................................................................. 21 PHARMACEUTICAL INFORMATION......................................................................... 21 CLINICAL TRIALS............. Lire le document complet